LCM
CHRS icon

Legato Capital Management’s Coherus Oncology CHRS Stock Holding History

Legato Capital Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-98,229
Closed -$102K – 579
2024
Q3 		$102K Hold
98,229
– – 0.01% 537
2024
Q2 		$170K Hold
98,229
– – 0.02% 524
2024
Q1 		$235K Hold
98,229
– – 0.03% 526
2023
Q4 		$327K Hold
98,229
– – 0.04% 484
2023
Q3 		$367K Buy
98,229
+39,191
+66% +$181K 0.05% 460
2023
Q2 		$252K Hold
59,038
– – 0.03% 496
2023
Q1 		$404K Hold
59,038
– – 0.07% 386
2022
Q4 		$468K Buy
+59,038
New +$454K 0.09% 358

Other funds holding CHRS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

Legato Capital Management's CHRS Position: Q4 2024 in Review

Legato Capital Management sold out of Coherus Oncology (CHRS) in Q4 2024, closing a stake of 98,229 shares — an estimated $102K sold.

Legato Capital Management first reported a position in CHRS in Q4 2022 and held it in 8 quarters. The position peaked at $468K in Q4 2022. 124 funds tracked by Wall St. Rank hold CHRS as of Q4 2024.

  • Legato Capital Management reported no remaining Coherus Oncology position as of Q4 2024 after selling out during the quarter.
  • Legato Capital Management sold 98,229 Coherus Oncology shares in Q4 2024, an estimated $102K.
  • Legato Capital Management first reported a position in Coherus Oncology in Q4 2022 and held it in 8 quarters.
  • Legato Capital Management's Coherus Oncology position peaked at $468K in Q4 2022.
  • 124 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2024.

Based on Legato Capital Management's 13F filing for Q4 2024, filed 29 Jan 2025.